PP436
BASELINE CHARACTERISTICS OF SARCOPENIC CANCER PATIENTS WITH DISEASE-RELATED MALNUTRITION (MRD) ACCORDING TO TYPE 2 DIABETES MELLITUS (T2DM) DIAGNOSTIC: ANYVIDA STUDY SUBANALYSIS
A. Castro Luna1 on behalf of AnyVida Group, I. Gonzalo Montesinos2,*, M. C. Dassen Llorca3 on behalf of AnyVida Group, C. Calderón Sánchez3 on behalf of AnyVida Group, G. Moreno Segura1 on behalf of AnyVida Group, S. Gago Gago2 on behalf of AnyVida Group, M. Crespo Yanguas3 on behalf of AnyVida Group, B. Cánovas Gaillemín1 on behalf of AnyVida Group, M. D. C. Bernal Asensio2 on behalf of AnyVida Group, R. Fernández Jiménez4 on behalf of AnyVida Group, J. M. García Almeida4 on behalf of AnyVida Group on behalf of AnyVida Group
1Endocrinology and Nutrition, Hospital Universitario de Toledo, Toledo, 2Endocrinology and Nutrition, Hospital Universitario de Fuenlabrada, Fuenlabrada, 3Endocrinology and Nutrition, Fundación Jiménez Díaz, Madrid, 4Endocrinology and Nutrition, Hospital Universitario Virgen de la Victoria, Málaga, Spain
Rationale: T2DM is a risk factor for sarcopenia, little is known about the specific clinical and morphofunctional phenotipe (MFP) of sarcopenic cancer patients with concomitant T2DM. The aim of this subanalysis was to compare baseline characteristics of sarcopenic patients according to the presence of T2DM
Methods: Ambulatory cancer patients with DRM who underwent nutritional and morphofunctional assessment at baseline. Only patients with European Working Group on Sarcopenia in Older People (EWGSOP2) criteria for sarcopenia were included, and were compared those with and without T2DM
Results: Among 106 sarcopenic patients, 27 had T2DM. The parameters with significant differences (Table 1). No significant differences were found in weight loss, calf circumference, ECOG or SARC-F score, phase angle, standardized phase angle, fat-free mass, BCM, ASMM and SMI, TUG, 30-second sit-to-stand, 5STS, lower-limb dynamometry or handgrip strength. Muscle ultrasound parameters were largely similar, although T2DM patients showed greater abdominal adiposity, except the ones in Table 1
Image:
Conclusion: Sarcopenic ambulatory cancer patients with DRM, those with T2DM showed a distinct phenotype characterized by older age, higher body weight and BMI, greater total and abdominal adiposity, and some biochemical differences related to iron and erythrocyte indices. In contrast, muscle-related morphofunctional parameters and physical performance were similar between groups. These findings suggest that, within sarcopenic oncology patients, T2DM may identify a subgroup with a more adiposity-predominant phenotype rather than a more severe muscle-functional impairment
References: Cruz-Jentoft AJ, et al. Age Ageing. 2019
Prado CM, et al. Sarcopenia and chemotherapy toxicity in cancer patients
Shachar SS, et al. Prognostic value of sarcopenia in oncology
Disclosure of Interest: None declared